Beyond Conventional Considerations: Newer Devices Used in Blood Pressure Measurement and Management

Advances in Chronic Kidney Disease

Volumn 18, Issue 1, 2011, Pages 48-54

  Townsend, Raymond R ^a,b   Sica, Domenic A ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

BP management

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIURETIC AGENT;

ADRENERGIC SYSTEM; AORTA PRESSURE; ARTERIOGRAPHY; BLOOD PRESSURE CUFF; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BLOOD VESSEL FUNCTION; CARDIOVASCULAR EQUIPMENT; CHRONIC KIDNEY DISEASE; HUMAN; HYPERTENSION; KIDNEY FAILURE; NONHUMAN; OSCILLOMETRY; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; PULSE WAVE; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTOLIC BLOOD PRESSURE; TONOMETRY;

ARTERIES; BAROREFLEX; BLOOD FLOW VELOCITY; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; BREATHING EXERCISES; CATHETER ABLATION; ELECTRIC STIMULATION THERAPY; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; PROGNOSIS; PULSATILE FLOW; RENAL INSUFFICIENCY, CHRONIC; RESPIRATORY THERAPY;

EID: 78651063444     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2010.11.002     Document Type: Review

References (48)

1. Pannier B., Guerin A.P., Marchais S.J., et al. Stiffness of capacitive and conduit arteries: prognostic significance for end-stage renal disease patients. Hypertension 2005, 45:592-596.
2. Bramwell J.C., Hill A.V. The velocity of the pulse wave in man. Proc Soc Lond (Biol) 1922, 93:298-306.
3. Guerin A.P., Blacher J., Pannier B., et al. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001, 103:987-992.
4. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: " Establishing normal and reference values." Eur Heart J 2010, 31:2338-2350.
5. Martyn C.N., Greenwald S.E. Impaired synthesis of elastin in walls of aorta and large conduit arteries during early development as an initiating event in pathogenesis of systemic hypertension. Lancet 1997, 350:953-955.
6. Harkness M.L., Harkness R.D., McDonald D.A. The collagen and elastin content of the arterial wall in the dog. Proc R Soc Lond B Biol Sci 1957, 146:541-551.
7. Bank A.J., Wang H., Holte J.E., et al. Contribution of collagen, elastin, and smooth muscle to in vivo human brachial artery wall stress and elastic modulus. Circulation 1996, 94:3263-3270.
8. London G.M., Marchais S.J., Guerin A.P., et al. Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients. Kidney Int Suppl 2003, 84:S88-S93.
9. Vlachopoulos C., Hirata K., O'Rourke M.F. Effect of sildenafil on arterial stiffness and wave reflection. Vasc Med 2003, 8:243-248.
10. Wilkinson I.B., MacCallum H., Hupperetz P.C., et al. Changes in the derived central pressure waveform and pulse pressure in response to angiotensin II and noradrenaline in man. J Physiol 2001, 530(Pt 3):541-550.
11. Townsend R.R., Wimmer N.J., Chirinos J.A., et al. Aortic PWV in chronic kidney disease: a CRIC ancillary study. Am J Hypertens 2010, 23:282-289.
12. Vlachopoulos C., Aznaouridis K., Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010, 55:1318-1327.
13. Moser M., Hebert P., Hennekens C.H. An overview of the meta-analyses of the hypertension treatment trials. J Am Coll Cardiol 1996, 151:1277-1279.
14. Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009, 338:1245-1253.
15. Jamerson K., Weber M.A., Bakris G.L., et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008, 359:2417-2428.
16. Dahlof B., Sever P.S., Poulter N.R., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, 366:895-906.
17. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
18. McEniery C.M., Yasmin McDonnell B., et al. Central pressure: variability and impact of cardiovascular risk factors. The Anglo-Cardiff Collaborative Trial II. Hypertension 2008, 51:1476-1482.
19. Katakam R., Townsend R.R. What's in a pulse?. J Clin Hypertens (Greenwich) 2006, 8:140-141.
20. Mitchell G.F. Effects of central arterial aging on the structure and function of the peripheral vasculature: implications for end-organ damage. J Appl Physiol 2008, 105:1652-1660.
21. Katakam R., Townsend R.R. What's in a pulse? Part 2. J Clin Hypertens (Greenwich) 2006, 8:288-290.
22. McEniery C.M., Yasmin Hall IR., et al. Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity: the Anglo-Cardiff Collaborative Trial (ACCT). J Am Coll Cardiol 2005, 46:1753-1760.
23. Laurent S., Cockcroft J., Van Bortel L., et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006, 27:2588-2605.
24. Vlachopoulos C., Aznaouridis K., O'Rourke M.F., et al. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J 2010, 31:1819-1822.
25. Takenaka T., Mimura T., Kanno Y., et al. Qualification of arterial stiffness as a risk factor to the progression of chronic kidney diseases. Am J Nephrol 2005, 25:417-424.
26. Taal M.W., Sigrist M.K., Fakis A., et al. Markers of arterial stiffness are risk factors for progression to end-stage renal disease among patients with chronic kidney disease stages 4 and 5. Nephron Clin Pract 2007, 107:c177-c181.
27. Safar M.E., Blacher J., Pannier B., et al. Central pulse pressure and mortality in end-stage renal disease. Hypertension 2002, 39:735-738.
28. Eddington H., Sinha S., Li E., et al. Factors associated with vascular stiffness: cross-sectional analysis from the Chronic Renal Insufficiency Standards Implementation Study. Nephron Clin Pract 2009, 112:c190-c198.
29. Hermans M.M., Henry R., Dekker J.M., et al. Estimated glomerular filtration rate and urinary albumin excretion are independently associated with greater arterial stiffness: the Hoorn Study. J Am Soc Nephrol 2007, 18:1942-1952.
30. Pramanik T., Sharma H.O., Mishra S., et al. Immediate effect of slow pace bhastrika pranayama on blood pressure and heart rate. J Altern Complement Med 2009, 15:293-295.
31. Nidich S.I., Rainforth M.V., Haaga D.A., et al. A randomized controlled trial on effects of the transcendental meditation program on blood pressure, psychological distress, and coping in young adults. Am J Hypertens 2009, 22:1326-1331.
32. Oneda B., Ortega K.C., Gusmao J.L., et al. Sympathetic nerve activity is decreased during device-guided slow breathing. Hypertens Res 2010, 33:708-712.
33. Resperate for hypertension. Med Lett Drugs Ther 2007, 49:55-56.
34. RESPeRATE. Available at: Accessed November 2, 2010. http://www.resperate.com/MD.
35. Parati G., Carretta R. Device-guided slow breathing as a non-pharmacological approach to antihypertensive treatment: efficacy, problems and perspectives. J Hypertens 2007, 25:57-61.
36. Lohmeier T.E. The sympathetic nervous system and long-term blood pressure regulation. Am J Hypertens 2001, 14(6 Pt 2):147S-154S.
37. Elliott W.J., Izzo J.L., White W.B., et al. Graded blood pressure reduction in hypertensive outpatients associated with use of a device to assist with slow breathing. J Clin Hypertens (Greenwich) 2004, 6:553-559.
38. Schwartz S.I., Griffith L.S., Neistadt A., et al. Chronic carotid sinus nerve stimulation in the treatment of essential hypertension. Am J Surg 1967, 114:5-15.
39. Sica D.A., Lohmeier T.E. Baroreflex activation for the treatment of hypertension: principles and practice. Expert Rev Med Devices 2006, 3:595-601.
40. Scheffers I.J., Kroon A.A., Tordoir J.H., et al. Rheos Baroreflex Hypertension Therapy System to treat resistant hypertension. Expert Rev Med Devices 2008, 5:33-39.
41. Illig K.A., Levy M., Sanchez L., et al. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. J Vasc Surg 2006, 44:1213-1218.
42. Scheffers I.J., Kroon A.A., Schmidli J., et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol 2010, 56:1254-1258.
43. Sica D.A., Bakris G., Bisognano J., et al. A phase III trial of barareflex activation therapy for resistant hypertension: trial design and baseline characteristics of the Rheos Pivotal Trial [abstract]. J Clin Hypertens 2010, 12(suppl 1). A-114.
44. Bakris G., Bisognano J., Nadim M., et al. Achievement of blood pressure goal in patients with resistant hypertension treated with baroreflex activation therapy(R) [abstract]. J Hypertens 2010, 28(suppl A):e282.
45. Converse R.L., Jacobsen T.L., Toto R.D., et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992, 327:1912-1918.
46. Krum H., Schlaich M., Whitbourn R., et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009, 373:1275-1281.
47. Schlaich M.P., Sobotka P.A., Krum H., et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009, 361:932-934.
48. Appel L.J., Wright J.T., Greene T., et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010, 363:918-929.